



PREVALENCE OF HPV DNA POSITIVITY AMONG HIV POSITIVE WOMEN

Supriti Kumari^{*1}, Sunita Malik², Harsha Gaikwad³, Gaurav Anand⁴, Nitin Tyagi⁵, Amresh Kumar Andilya⁶, Shivangi Khunger⁷, Jagdish Prasad⁸ and Bhaskar Charana Kabi⁹

¹MBBS, MS Obstetrics & Gynaecology, Department of Obstetrics & Gynaecology, Vardhman Mahavir Medical College & Safdarjung Hospital, NewDelhi.

²Professor, Department of Obstetrics & Gynaecology, Vardhman Mahavir Medical College & Safdarjung Hospital, NewDelhi.

³Professor, Department of Obstetrics & gynaecology, VardhmanMahavir Medical College & Safdarjung Hospital, NewDelhi.

⁴MBBS, Government Vellore Medical College.

⁵MBBS, MD (Post Graduate Student), Department of Biochemistry, VardhmanMahavir Medical College & Safdarjung Hospital, New Delhi.

⁶MS Obstetrics & gynaecology, Department of Obstetrics & gynaecology, VardhmanMahavir Medical College & Safdarjung Hospital, NewDelhi.

⁷DNB Obstetrics & gynaecology, SPS Hospitals, Ludhiana.

⁸Professor, Department of CTVS, VardhmanMahavir Medical College & Safdarjung Hospital, NewDelhi.

⁹Director-Professor, Department of Biochemistry, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi.

***Corresponding Author: Dr. Supriti Kumari**

MBBS, MS Obstetrics & Gynaecology, Department of Obstetrics & Gynaecology, Vardhman Mahavir Medical College & Safdarjung Hospital, NewDelhi.

Article Received on 29/09/2018

Article Revised on 19/10/2018

Article Accepted on 09/11/2018

INTRODUCTION

There are 110 types of HPV infections known and out of which only half infect the genital tract. According to IARC WHO classification only 13 types are carcinogenic and rest 7 are possibly carcinogenic. Out of carcinogenic ones are HPV -16,18,31,33,35,39,45, 51, 52, 56,58, 59 and 68.^[1] HIV infection causes impaired cell mediated immunity which in turn is responsible for persistent HPV infection & increase risk for abnormal PAP Test.^[2,3] HIV seropositive women if affected by high risk HPV types it progresses rapidly to precancerous lesion and then cervical cancer as compared to seronegative women. Frequent screening and elimination of precancerous lesion under cervical cancer prevention program is the only way of blocking the oncogenesis. Immunosuppressed state of HIV prevents host from effectively eliminating HPV from the target tissues and make it prone for CIN and precursor lesion. The relationship among human immunodeficiency virus, Human papilloma virus, and development of Cervical Intraepithelial Neoplasia are undoubtedly complex and incompletely understood. Present study is an attempt to find out the prevalence and relationship of HPV infection in HIV positive women.

AIMS AND OBJECTIVES

This study was conducted to determine the gynaecologic characteristics related with HIV infection, and also to find out prevalence of HPV DNA positivity in HIV positive women.

MATERIAL AND METHODS

This was a cross-sectional, case control study which was conducted in the Department of Obstetrics & Gynaecology and Antiretroviral Treatment (ART) clinic of a tertiary care centre of North India after ethical clearance from the Institute. Study was conducted on total 190 women. In the study group (Group A) 95 HIV positive women were included from Art clinic and equal numbers of HIV negative women were recruited as controls (Group B). Controls were recruited from women

of almost same age and parity coming to gynaecology OPD for any gynaecological problem or advice.

Inclusion Criteria

1. All consenting HIV positive women during the study period of one year.

Exclusion Criteria

1. Subjects not willing to participate in the study.
2. Patient not giving the consent for the study.

All subjects were counselled and an informed consent was taken. HIV status of control group was confirmed by blood test (ELISA). All HIV positive women of study group were also assessed for CD4 cells counts. They were evaluated thoroughly by history and examination.

Specimen was collected from the cervix using cytobrush for HPV DNA testing. HPV DNA was detected with the polymerase chain reaction (PCR) based method using HPV L1 consensus primer (MY11 and MY09) and control primer set PC04/GH20. Positive sample was defined as those containing an ethidium-bromide-stained band of the correct mol. wt. (450bps) after amplification and 1.5% agarose gel electrophoresis. Furthermore, adequacy of negative sample for PCR analysis, i.e. absence of inhibitors, was assessed by the amplification of a fragment of β -globin gene. For HPV DNA-positive sample, and typing was done by PCR using type specific primers for HPV16, HPV18, HPV6 and HPV11.

Data analysis: Data analysis was done using the relevant statistical tool. The statistical significance was determined by using Chi square test with 5 percent level of significance ($P < 0.5$), and Power of the study was

90%. Women were compared using student t test for continuous variable and Chi – Square for categorical variables factor like age, CD4 count, HIV -1 RNA, education employment ,parity ,complaints. number of sexual partners and age of first intercourse.

RESULTS

While comparing the Demographic characteristics of cases and controls, no significant difference was found in terms of age, parity, socioeconomic status, educational status etc. Most of the subjects of both groups belonged to age group 25-34 years. Mean age of the cases was 31.9 years. Most of the women in both groups were multiparous. Comparing the contraceptive use condom was the most used contraceptive in HIV positive women [16%] and Intrauterine contraceptive device was the most used contraceptive in HIV negative women [7.4%].

Table 1: Distribution of clinical symptoms in group A and group B.

Clinical symptoms	HIV Positive (Group A)		HIV Negative (Group B)	
	No	%	No.	%
Discharge	17.0	17.9	15.0	15.8
Dysuria	6.0	6.3	3.0	3.2
Infertility	0.0	0.0	3.0	3.2
Itchiness of vulva	4.0	4.2	0.0	0.0
Menorrhagia	0.0	0.0	9.0	8.4
Pain in lower abdomen	7.0	7.4	16.0	16.8
Post coital bleeding	0.0	0.0	1.0	1.1
Prolapse	1.0	1.1	1.0	1.1

$P = 0.006$

Majority of women had no symptoms, percentage of such women was 63.2% in group A and 49.5% in group B. Discharge per vaginum was the most common symptom in both the groups.

Mucoid discharge was most common presentation [27.36% women in group A and 21.1% in group B] and curdy white discharge was least present [7.36% and 0% respectively].

Table 2: Distribution of HPV among study and control group.

HPV	HIV positive (group A)		HIV Negative (group B)	
	No(95)	%	No(95)	%
Negative	78	82.3	88	92.6
Positive	17	18.6	7	7.4
HPV 16 type	16	17.6	7	7.4
HPV 16+18 type	1	1	0	0

$P = 0.043$

There was significant difference in association of HPV DNA between study and control group ($p = 0.043$). The percentage of HPV DNA positivity among study group was 18.6% and in control group it was only 7.4%. Out of positive HPV groups, HPV 16 was more prevalent in both groups (17.6% v/s 7.4%). Combined HPV 16 +18 was seen only in one patient in group A.

Out of 95 HIV positive women 27.37% had CD4 count below 249, 44.21% women had CD4 count between 250-499 and 28.42% women had CD4 count > 500 .




Table 4: CD4 count and HPV.

Pearson correlation (-0.982)

CD4 count <249 HPV DNA positivity were 53% and when increased number of CD4 counts in HIV positive women decrease the percentage of HPV DNA positivity (CD4 counts between 250-499 percentage of HPV DNA positivity were 5 and CD4 count >500 HPV DNA positivity was 19%).

There was no significant association found between ART treatment and HPV DNA positivity. Out of 17 HPV positive, 2 had not started ART treatment and 15 were on ART treatment. HPV positivity was more (88%) in women in taking ART VS 12% in women not taking the same. Out of 95 HIV positive twenty seven women were not on any ART treatment. Women who were taking ART for 6-12 months duration were 15.8% for 12.1-24 months duration were 15.8% and for more than 24 months were 28.4%.

DISCUSSION

Acquisition of both Human papilloma Virus and Human immunodeficiency virus is related to common behavioural risk factors such as multiple sex partners which make the assessment of casual relationship difficult to assess. The estimated time interval between initial HPV infection and development of cervical cancer is 20 years and dysplasia occurs in stages. Persistent HPV infection may lead to CIN 1 which usually resolve on its own in majority of cases. Only in minority of cases these lesions progress to CIN 2, CIN 3, adenocarcinoma in situ and cervical cancer. If HPV infection occurs in HIV positive women there is much more rapid progression to higher grade and invasive lesions. In fact chances of detection of HPV infection increases rapidly within early years of seroconversion which is suggestive of mucosal immune dysfunction or HIV related change in the molecular pathway leading to cervical cancer.^[4] Immunosuppression makes the infected women more prone for persistent infection and progressive dysfunction in immune system along with failure to curb the neoplastic changes. In present study HPV infection

was significantly higher in study group than control group [18.6% Vs 7.4%]. This observation can be explained by the fact that immunosuppression due to HIV infection causes impaired clearance of HPV thereby causing positivity for the same more in the study group.^[5,6] Another study has reported co-infection with HPV infection was seen in 63.2% in cases as compared with 30.4% in HIV seronegative women.^[7] High risk HPV type like HPV 18 were exclusively seen in HIV positive women and HPV 16 was significantly higher in study group [17% vs 7.4%]. Another author reported chances of Abnormal PAP smear to be 4.3 fold higher in HIV positive women.^[8]

In present study we also found the prevalence of HPV DNA significantly higher in HIV positive women than in controls [18.6% Vs 7.4 %]. Although the difference is much higher in other studies in comparison to present study can be explained due to variation in sample size. Although there are some studies which after years of observation have reported that most abnormal Papanicolaou tests in HIV –Seropositive women are atypical or low grade lesions not the high grade lesions leading to the high grade lesions leading to precancerous state.^[9,10] HPV 16, 18 and other high HPV Types are the risk factors of cervical cancer and for cervical intraepithelial neoplasia and its precursors.^[7,9,10,11] A significant correlation was found between CD4 count and HPV DNA reports with p value 0.121 & Pearson correlation coefficient - 0.982. 53% of HPV DNA positive women had CD4 count < 250 / mm³, 31% had CD4 count 250-499/ mm³. Many other studies have shown the similar observation.^[12,13] In present study no significant association was found between duration of ART and HPV positivity. it was observed that the HPV DNA positivity was more i.e. 88% in women taking HAART versus 12% in women not taking the same. This could be because the women recruited for HAART were the ones with low CD4 count in which the lower immunity caused higher prevalence of HPV infection. Due to lack of follow up in our study a definite conclusion regarding the HPV DNA positivity over a time period and regression of SIL in women taking HAART could not be made. Various studies have shown a contrary picture where the prevalence of HPV was lower in women taking HAART. Linda Ahdieh-Grant et al demonstrated that out of 312 women, 141 had lesions that regressed to normal cytology, with a mean time to regression of 2.7 years after HAART was introduced.^[14] However in a study conducted by Paula Schuman et al it was found that SIL regression was less likely among HIV positive women with higher viral load and that HAART had no beneficial effect.^[15] Observation is supported by a recent systemic review from Sub Saharan Countries.^[6] Another aspect of this observation is that initiation of ART increases longevity. Moreover frequent contact with health facility increases chances of screening and diagnosis of cervical lesions.

CONCLUSION

It is inferred that the prevalence of HPV DNA positivity is higher amongst HIV positive women. Also, there is an association between HPV DNA positivity and CD4 counts which showed higher prevalence of HPV infection in subjects with low CD4 counts.

REFERENCES

- Kim J, Kim BK, Lee CH, Seo SS, Park SY, Roh JW. Human papillomavirus genotypes and cofactors causing cervical intraepithelial neoplasia and cervical cancer in Korean women. *Int J Gynecol Cancer.*, 2012 Nov; 22(9): 1570-6. doi: 10.1097/IGC.0b013e31826aa5f9.
- Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, et al. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. *J Natl Cancer Inst.*, 1999; 91: 226–36.
- Massad LS, Seaberg EC, Wright RL, Darragh T, Lee YC, Colie C, et al. Squamous cervical lesions in women with human immunodeficiency virus: long-term follow up. *Obstet Gynecol*, 2008; 111: 1388–93.
- Wang C et al. Rapid rise in detection of human papillomavirus (HPV) infection soon after incident HIV infection among South African women. *J Infect Dis.*, 2011; 203(4): 479-86.
- Denny LA, Franceschi S, de Sanjosé S, Heard I, Moscicki AB, Palefsky J Human papillomavirus, human immunodeficiency virus and immunosuppression, *Vaccine.*, 2012 Nov 20; 30 Suppl 5: F168-74. doi: 10.1016/j.vaccine.2012.06.045.
- Menon S, Rossi R, Zdraveska N, Kariisa M, Acharya SD, Vanden Broeck D, Callens S. Associations between highly active antiretroviral therapy and the presence of HPV, premalignant and malignant cervical lesions in sub-Saharan Africa, a systematic review: current evidence and directions for future research. *BMJ Open.*, 2017 Aug 4; 7(8): e015123. doi: 10.1136/bmjopen-2016-015123. Review. PMID:28780541
- Massad LS, Riester KA, Anastos KM, Fruchter RG, Palefsky JM, Burk RD et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. *J Acq Imm Defic Syndr*, 1999; 21: 33-41.
- Mitchell Maiman, Rachel G. Fruchter, Alexander sedlis, Joseph Feldman, Patrickchen, Robert D. Burk and Howard Minkoff: Prevalence, Risk factor, and Accuracy of Cytologic screening for cervical intraepithelial neoplasia in women with the Human Immunodeficiency virus: *Gynecologic oncology*, 1998; 68: 233-23. *Cancer (phila)* 74: 1888-1901.
- Massad LS, Seaberg EC, Wright RL, et al. Squamous cervical lesions in women with human immunodeficiency virus: long-term follow-up. *Obstet Gynecol*, 2008; 111: 1388-93.
- Massad LS, Xie X, D'Souza G, et al. Incidence of cervical precancers among HIV-seropositive women. *Am J Obstet Gynecol*, 2015; 212: 606.e1-8.
- Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. *J Natl Cancer Inst*, 1999; 91: 226-36.
- Hanisch RA, Sow PS, Toure M, Dem A, Dembele B, Toure P, Winer RL, Hughes JP, Gottlieb GS, Feng Q, Kiviat NB, Hawes SE, for the University of Washington-Dakar HIV and Cervical Cancer Study Group Influence of HIV-1 and/or HIV-2 infection and CD4 count on cervical HPV DNA detection in women from Senegal, West Africa, *J Clin Virol*. Author manuscript; available in PMC, 2014 Dec 1.
- Published in final edited form as: *J Clin Virol.*, 2013 Dec; 58(4): 696–702.
- Madan A., Patil S., Nakates L., A Study of Pap Smear in HIV-Positive Females, *The Journal of Obstetrics and Gynecology of India* (November–December, 2016; 66(6): 453–459 DOI 10.1007/s13224-016-0908-9.
- Grant LA, Li R, Levine AM, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus positive women. *J Nat Cancer Inst*, 2004; 96(14): 1070-1075.
- Schuman P, Ohmit SE, Klein RS, Duerr A, Cu-Uvin S, Jamieson DJ, et al. Longitudinal study of cervical squamous intraepithelial lesion in Human Immunodeficiency virus (HIV)-Seropositive and at risk HIV seronegative women. *The Journal of Infection Disease*, 2003; 188: 128-36.
- Hong H, He TF, Ni HX, Zhang S, Xu GZ. Prevalence and genotype distribution of HPV infection among women in Ningbo, China. *Int J Gynaecol Obstet*, 2015; 131: 96–99.
- Sammarco ML, Ucciferri C, Tamburro M, Falasca K, Ripabelli G, Vecchiet J. High prevalence of human papillomavirus type 58 in HIV infected men who have sex with men: A preliminary report in Central Italy. *J Med Virol*, 2016; 88: 911–914.
- Liu G, Markowitz LE, Hariri S, Panicker G, Unger ER. Seroprevalence of 9 human papillomavirus types in the United States, 2005–2006. *J Infect Dis.*, 2016; 213: 191–198.
- Petrosky E, Bocchini JA, Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Centers for Disease Control and Prevention (CDC): Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. *MMWR Morb Mortal Wkly Rep.*, 2015; 64: 300–304.